76 results about "Peptide molecule" patented technology

The invention discloses a bidirectional reversible conversion method and system between a peptide molecule SMILES and a sequence expression. The core innovation lies in that a new sequence description syntax is defined to retain information of a polypeptide special bond and specific modification of amino acid; a main chain atom index and adjacency traversal topology identification algorithm is adopted, and end group and topology integrated detection and coding are carried out; a residue recognition algorithm for main chain cutting and template library matching is compatible with any standard or non-standard amino acid residues, an extensible end group library / monomer template library and an automatic increment mechanism, and automatic recognition and sequence annotation of S-S disulfide bonds; the invention relates to a high-fidelity assembly algorithm of HELM anchor points and topology aware cyclic peptide processing. The method solves the problems of incapability of supporting a complex polypeptide topological structure, poor reversibility, insufficient expansibility of a monomer library and the like in the prior art, can be widely applied to scenes of quantitative structure-activity relationship model construction, large-scale polypeptide data cleaning and the like, and has remarkable practicability and innovativeness.

The invention belongs to the technical field of biological fermentation, and particularly relates to ganoderma lucidum polypeptide and a preparation method and application thereof. The preparation method comprises the following steps: (1) taking ganoderma lucidum powder, adding water, and cooking to obtain a mixture 1; (2) adding bacillus subtilis liquid into the mixture 1, and fermenting to obtain ganoderma lucidum polypeptide fermentation liquid bacteria liquid; (3) adding neutral protease into the ganoderma lucidum polypeptide fermentation liquid for primary enzymolysis, and then adding aminopeptidase for secondary enzymolysis to obtain ganoderma lucidum polypeptide enzymatic hydrolysate; and (4) filtering, concentrating and spray-drying the lucid ganoderma polypeptide enzymatic hydrolysate to obtain the lucid ganoderma polypeptide. The molecular weight of the ganoderma lucidum polypeptide ranges from 200 Da to 5000 Da, molecular weight distribution is uniform, the polypeptide content can reach 31.11% at most, the ganoderma lucidum polypeptide can be applied to functional cosmetics, and the application range of the ganoderma lucidum polypeptide is widened.

The invention relates to the technical field of fluid circulation of collagen peptide production equipment, in particular to a collagen peptide mechanical seal water circulation system which comprises an intelligent control unit, a cooling unit and an ultrasonic descaling unit. Converting the vibration spectrum into a peptide molecule aggregation tendency coefficient, correcting a viscosity predicted value to generate a flow control weight, allocating resources to a cooling unit according to a hydrolysis risk thermodynamic diagram, directionally cooling a high-risk area, activating an ultrasonic descaling unit and reducing the flow when the aggregation coefficient continuously rises and exceeds a limit, the system generates cooperative control quantity through rolling of a three-dimensional dynamic weight matrix, synchronously adjusts the rotating speed of a water pump, the opening degree of a cooling valve and ultrasonic power, solves the problems of unstable flowing, peptide chain hydrolysis and aggregation scaling, and guarantees production stability and product quality.

The invention belongs to the technical field of biochemistry and functional polymer materials, and particularly relates to a polysaccharide-oligopeptide co-assembled intestinal flora regulation and control material and a preparation method thereof. The material is prepared from imine-boric acid ester double dynamic crosslinking modified chitosan, glycyl-tryptophan dipeptide, sodium lactate, citric acid, glycerol and a phosphate buffer solution. A reversible imine bond and a borate bond are introduced into chitosan molecules to construct a polysaccharide network with a double-dynamic crosslinking characteristic, and then the polysaccharide network and oligopeptide molecules are synergistically self-assembled to form a three-dimensional gel structure. The material has pH responsiveness, self-repairing property and slow-release function, and can realize continuous release of short peptides and selective regulation and control of probiotics in an intestinal environment. The prepared material is high in gel strength, good in structural stability and stable in oligopeptide release, and has remarkable promotion and inhibition selectivity on intestinal flora. The method provides an innovative co-assembly strategy for polysaccharide functionalization and micro-ecological intervention, and has a good application prospect.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

The invention relates to a hydrophobic tripeptide molecule, a crystal constructed by the hydrophobic tripeptide molecule and application of the hydrophobic tripeptide molecule in a piezoelectric device. The structural formula of the polypeptide molecule is shown as a formula (I). The polypeptide molecule can form a micron-sized crystal through a heating-cooling method, and the interior of the micron-sized crystal is of an asymmetric structure and is of a triclinic system. A crystal formed by the polypeptide molecule has a relatively high piezoelectric coefficient (21.5 pC / N), a sandwich type piezoelectric device is constructed by using the crystal, and the output voltage can reach 2.57 V, which is the highest value of an oligopeptide nano material prepared in an aqueous solution. Therefore, the invention provides a method for forming the tripeptide crystal, and provides a potential strategy for development of piezoelectric materials based on short peptide self-assembly. (I)

The present invention relates to the field of biomedicine and antibody engineering. Specifically, it relates to mono and multispecific multivalent single chain polypeptide molecules and derivatives thereof, preferably to multispecific single chain (tandem) trimerbodies with defined stoichiometry, to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, use as diagnostics or imaging reagents and combination therapies using thereof.

The invention belongs to the technical field of protein beverages, and particularly relates to a composite peptide beverage and a preparation process thereof. The active ingredients of the drink comprise calf thymosin, cattle spleen protein peptide, hemoglobin peptide, bone collagen peptide and collagen peptide in a weight ratio of (2-3): 1: 1: 1: 1. The pH value of the system is adjusted to 3.5-4.5, so that each peptide molecule is positively charged under the acidic condition, the electrostatic repulsion and hydration among molecules are enhanced, and bitter groups are effectively masked. The flavoring agent is compounded by DL-malic acid, crystalline fructose, xylitol and sucralose according to the weight ratio of (0.6-1): 1: 0.4: (0.03-0.04), and the sour and sweet taste and flavor coordination are synergistically improved. The preparation method comprises the following steps: dissolving the DL-malic acid in purified water, dissolving the uniformly mixed active components in purified water at 40-60 DEG C, respectively adding other flavoring agents, stabilizing agents and essence, and finally filtering to obtain the product. The problem of bad flavor of the peptide is solved, so that the beverage is appropriate in taste, harmonious in flavor and easy to accept.

The invention discloses a preparation process optimization system and method of soybean enzymolysis protein peptides, and relates to the technical field of bio-enzymes, initial enzymolysis condition evaluation is carried out on soybean protein raw materials, an initial enzymolysis parameter combination is obtained, an experimental enzymolysis reaction is carried out, a hydrolysis degree change curve is obtained, whether the hydrolysis degree increase rate reaches a preset threshold value or not is judged, and if yes, the soybean enzymolysis protein peptides are obtained. If the peptide molecular weight distribution meets the target range, continuing the enzymolysis reaction, and when the peptide molecular weight distribution meets the target range, separating and purifying an enzymolysis product, recording a final enzymolysis parameter combination, judging whether a preset functional index is met or not, and if so, taking the final enzymolysis parameter combination as an optimized preparation process; if not, dynamically adjusting a preset threshold value or a target range; and if not, adjusting parameters in the initial enzymolysis parameter combination to form an optimized enzymolysis parameter combination. The functional activity and the stability of a protein peptide product are remarkably improved, and the production cost is reduced.

The application discloses an immunoregulatory peptide BugaCATH and application thereof, and belongs to the field of biomedicine. Buga The CATH is a cyclic polypeptide with a pair of intramolecular disulfide bond composed of a sixth cysteine and a thirteenth cysteine, and has a molecular weight of 3156.67 Dalton and an isoelectric point of 8.76, wherein the amino acid sequence is shown as SEQ ID NO: 2. Buga The gene (GenBank accession: OQ870533) of the CATH precursor is composed of 663 nucleotide sequences, and the nucleotide sequence is shown as SEQ ID NO: 1; wherein the nucleotide at the positions of 322-448 is the immunoregulatory peptide Buga The encoding gene of the CATH. The immunoregulatory peptide Buga The application of the CATH in the preparation of a treatment drug for promoting skin wound repair.

This invention discloses an environmentally friendly curcumin nanocrystal and its preparation method, relating to the field of nanoparticle technology. The nanocrystal has a core-shell structure, with a core of curcumin crystals and a shell of hepatin peptide molecules bonded together by intermolecular forces. The average particle size of the nanocrystal is 50-200 nanometers, and it is completely dispersed and stable in an aqueous phase, containing no organic solvents or synthetic surfactants. This invention utilizes a pectin-chitosan complex to microencapsulate the nanocrystal, enabling it to resist gastric acid degradation and target release to the colon, thus precisely acting on the gut-hepatic axis and significantly improving bioavailability and hepatoprotective efficacy. While completely avoiding organic solvents and synthetic stabilizers, it simultaneously solves four major industry challenges related to curcumin: solubility, stability, targeted delivery, and synergistic efficacy, providing a new technical path for developing high-end, naturally derived hepatoprotective products.

The invention relates to the technical field of deep processing of egg products, in particular to egg white peptide / polyphenol / metal ion ternary synergistically assembled composite particles and application of the egg white peptide / polyphenol / metal ion ternary synergistically assembled composite particles in stable emulsions.The egg white peptide / polyphenol / metal ion ternary synergistically assembled composite particles are prepared by pre-assembling metal ions and polyphenol to form a metal-phenolic network and synergistically assembling the metal-phenolic network and egg white peptide through an anti-solvent coprecipitation method. The egg white peptide / polyphenol / metal ion ternary synergistic assembly composite particles are formed. Compared with unassembled egg white peptide, the colloidal property of the composite particle is regulated and controlled, the absolute value of surface charge is reduced, the interface hydrophobicity is enhanced, and the egg white peptide molecule conformation is promoted to be converted into an ordered secondary structure mainly comprising beta-folding. The composite particle can be used as a novel stabilizer for constructing an emulsion, and the obtained emulsion is uniform in droplet size, good in dispersity and still stable under the environmental stress conditions of heating, freezing and thawing, different pH values, salt ion strength and the like. The invention provides a new technical approach for the application of the egg white source active peptide in emulsion and functional food.

The invention belongs to the field of microbial technology and plant disease and pest control, and particularly relates to decapeptide, a product comprising the decapeptide, a preparation method of the decapeptide and application of the decapeptide. The decapeptide is shown as a formula I or a derivative of the decapeptide shown as the formula I. In the formula I, R1 or / and R2 is-OH or at least one of R1 and R2 is R3 is-CH3 or-CH (CH3) 2, and n is a positive integer. The decapeptide molecule is unique in structure, can effectively inhibit phytopathogen, and is low in effective concentration and high in bacteriostasis rate. In addition, the method also has a certain broad spectrum.

This invention belongs to the field of biomedical technology and discloses a method for preparing oil-soluble nonapeptide-1 and its application. This method covalently links a C8–C18 hydrophobic alkyl chain to the Arg guanidine group at the 4th position and / or the Lysε-amino group at the 7th position of nonapeptide-1, obtaining a molecularly oil-soluble derivative that retains tyrosinase inhibitory activity. This invention achieves a transformation from physical solubilization to chemical modification by introducing structurally optimized hydrophobic groups at specific sites in the nonapeptide-1 molecule. The resulting oil-soluble nonapeptide-1 exhibits molecular-level dispersion in oils and is thermodynamically stable, requiring no external carrier or high proportion of excipients, effectively solving the problems of precipitation, inactivation, and deterioration of skin feel caused by interfacial tension in existing technologies. Simultaneously, its tyrosinase inhibitory activity is highly preserved, and it possesses excellent transdermal properties. This technical solution lays a solid foundation for the efficient, stable, and safe application of nonapeptide-1 in high-end oil-based skincare products, demonstrating significant technological advancement and industrialization value.

The application discloses collagen tripeptide and a preparation method and application thereof, and belongs to the technical field of bioengineering. The preparation method comprises the following steps: obtaining bacillus velezensis with high collagenase yield through separation and identification, the bacillus velezensis belongs to probiotics, and high-activity collagenase is obtained through fermentation culture and purification; taking shark cartilage or blue fish skin as raw materials, and obtaining collagen tripeptide through the following steps of combined enzymolysis of alkaline protease and collagenase after pretreatment, inactivation, centrifugal separation and freeze-drying. The collagen tripeptide prepared by the application has a molecular weight of less than 500 Dalton, contains active components such as GHK tripeptide, is easy to absorb and has high safety, and can be used for preparing antioxidant products, anti-inflammatory products, memory-enhancing products or immunity-enhancing products. The application solves the problems of unsafe collagenase source and low collagen tripeptide preparation efficiency, and has a good industrial application prospect.

This invention discloses a umami peptide derived from soy sauce, belonging to the field of bioactive peptides. The amino acid sequence of the umami peptide is GAAGAAD. This invention identifies and screens a novel umami peptide from soy sauce peptide components eluted with 60% ethanol using virtual screening technology. The synthesized umami peptide, verified by an electronic tongue, exhibits good umami flavor and a synergistic umami-enhancing effect with monosodium glutamate (MSG). The key amino acids and mechanism of action of the umami peptide in binding to the umami receptors T1R1 / T1R3 were also investigated, providing a reference for studying the umami-enhancing mechanism of umami peptides. This peptide has a small molecular weight, is safe, non-toxic, and non-allergenic, and has good water solubility, making it valuable for use as a condiment or food additive in food.

To provide a combination chemotherapy exhibiting a large therapeutic effect on cancer, especially bladder cancer.SOLUTION: There is provided a first chemotherapeutic agent and a second chemotherapeutic agent for use in the treatment of cancer, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of a peptide of at least 10 amino acids comprising an alpha-helical structure and oleic acid or oleate in a ratio of at least 3 oleic acid or oleate molecules per peptide molecule. Provided are either a first chemotherapeutic agent or a second chemotherapeutic agent for use in cancer therapy, for use in conjunction with other chemotherapeutic agents, pharmaceutical compositions related thereto, and methods of treatment.SELECTED DRAWING: None

The present application relates to oxytocin receptor selective cyclic peptide molecules and their use in the preparation of anti neuropathic pain drugs. The present application provides an oxytocin receptor (OXTR) selective cyclic peptide molecule, the OXTR selective cyclic peptide molecule comprises an amino acid sequence as shown in formula I and salts thereof: formula I: [CYIX1NC]X2X3G-NH2. The OXTR selective polypeptide provided by the present application, by establishing a bioluminescence resonance energy transfer high-throughput screening system for OXTR, detecting the G alpha q protein decoupling triggered after the polypeptide ligand activates OXTR, in order to screen out candidate molecules that can selectively agonize OXTR and play an anti neuropathic pain, and is expected to realize the discovery of anti neuropathic pain new drugs.

The invention belongs to the technical field of biological medicine and nano delivery, and particularly relates to a protein crown delivery system and a preparation method and application thereof. According to the protein crown delivery system provided by the invention, the specific bifunctional polypeptide is utilized to modify the surfaces of the gold nanoparticles, and various active proteins can be efficiently and stably combined to form the protein crown, so that the active proteins can be delivered in cells. Specifically, rich side chain groups of bifunctional polypeptide molecules are utilized to solve the problem of few binding sites between a protein crown delivery system and protein molecules, so that the protein crown delivery system and the protein molecules are combined and assembled through non-covalent interaction to form a uniform and stable protein crown structure, and the binding efficiency of a carrier and protein is improved; therefore, a universal, efficient and safe protein nano intracellular delivery carrier is constructed. The protein crown delivery system provided by the invention can be coupled with various types of proteins, and keeps the biological activity and function of the proteins, so that intracellular delivery can be performed on the proteins with different activities.

The present application relates to the technical field of bioactive peptide preparation, and discloses a bird's nest peptide composition for activating long-life gene SIRT1 and a directional enzymatic preparation method and application thereof.The bird's nest peptide composition comprises four peptide segments shown in SEQ ID NO:1 to SEQ ID NO:4 with a molecular weight of 100-500 Da.The method comprises the following steps: subjecting bird's nest raw materials to pretreatment, directional enzymatic hydrolysis of composite enzymes, membrane concentration and spray drying to obtain intermediate peptides with a molecular weight of less than 3 kDa, and then subjecting the intermediate peptides to separation and purification to finally obtain the bird's nest peptide composition with a target molecular weight range.The present application solves the problems of wide molecular weight distribution and insufficient functional targeting of traditional bird's nest peptides by controlling the molecular weight range and the enzymatic hydrolysis process.The bird's nest peptide composition can significantly up-regulate the expression of aging genes in a zebrafish aging model and improve oxidative stress indicators, and has excellent anti-aging activity.

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

This invention discloses a type 1 diabetes vaccine based on autoantigen polypeptide molecules. The invention provides a series of immunogenic autoantigens as active ingredients in type 1 diabetes vaccines. This invention utilizes computer-simulated amino acid mutations of type 1 diabetes autoantigen sequences obtained from type 1 diabetes patients, supplemented by rational design based on the HLA-peptide-TCR ternary complex structure; targeted optimization enhances the binding affinity between the antigen and immune molecules, thereby achieving significant proliferation of type 1 diabetes-related CD4+ T lymphocytes. The autoantigens of this invention will serve as the basis for the development of type 1 diabetes vaccines in the form of artificially synthesized polypeptide molecules.

The invention relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit. Endophalin is also called as brain endophine, is a morphine-like biochemical synthetic hormone and is secreted by pituitary gland. Beta-enorphin is small in molecular weight and poor in immunogenicity and has various structural analogues, so that when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to the design and synthesis of a beta-enorphin hapten, the preparation of a beta-enorphin complete antigen and an anti-beta-enorphin antibody, a method for measuring the concentration of beta-enorphin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a beta-ennorphin derivative. The beta-ennorphin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

The invention discloses a USAG-1 recombinant protein targeted delivery system based on multi-enzyme logic gating and a preparation method, and mainly relates to crossing of biological medicine and nanotechnology. Comprising the following steps: S1, a C-terminal fusion nuclear localization sequence PKKKRKV of a recombinant USAG-1 protein expressed by CHO cells, and the purity of the recombinant USAG-1 protein is greater than or equal to 98%; s2, preparing core-shell structure nanoparticles, wherein the core is PLGA loaded BMP-2, and the drug loading capacity is 2.5-4.2 [mu] g / mg; the outer-layer lipid membrane is composed of DSPC / DSPG according to the ratio of 7: 3, and the surface embedded USAG-1 molecular density is greater than or equal to 1 * 10 / mu m < 2 >; s3, the surface co-modified EGFR antibody and the RGDfK peptide are connected through a thiol-maleimide bond and a PEG2000 spacer arm according to the molecular ratio of 1: 1.6 + / -0.2, the coding sequence of the recombinant USAG-1 is regulated and controlled by an MMP-9 response promoter, and the promoter is located in MMP-9gt; and the expression is activated at 20nM. The system has the beneficial effects that time-space precise delivery of the bone metabolism related protein USAG-1 is realized through a multi-enzyme logic gating mechanism, and the system is suitable for treatment of bone metabolism disorder diseases such as osteosarcoma and alveolar bone defect.

Provides herein are multifunctional polypeptide molecules comprising T cell receptor variable beta-binding moieties and cytokines and methods of treating conditions or diseases in a subject using the same.

This invention provides the preparation and application of a class of artificial peptide transporters for promoting transmembrane delivery of peptide drugs. The general structural formula is as follows: The compound involved in this invention consists of three parts: (1) a diamide structure as an anion-binding unit, which binds to the carboxyl anion of the peptide molecule; (2) a crown ether as a cation-binding unit, which binds to the amino cation of the peptide molecule; and (3) a hydrophobic side chain: connecting the anion-binding unit and the cation-binding unit, so that the whole molecule can act as molecular tweezers to form a stable complex with the peptide drug and encapsulate it in a hydrophobic environment to promote its transmembrane transport. The compound obtained in this application has inexpensive raw materials, is easy to synthesize, and significantly improves the bioavailability of peptide drugs. It has shown significant synergistic anticancer activity in both in vitro and in vivo experiments, and therefore has great potential as a pharmaceutical excipient.

Described herein are methods and compositions for treatment of diabetes and / or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, said signaling related hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body's own endocrine system to treat diabetes, which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention.

The invention discloses a high-affinity HER2 targeting polycyclic peptide molecule and a preparation method and application thereof.The preparation method comprises the steps that affinity optimization is conducted on initial HER2 targeting polycyclic peptides obtained through phage display library screening by combining a yeast display technology with an error-prone PCR directed evolution system, and a series of high-affinity disulfide bond-rich polycyclic peptides (DDMP) are obtained; the polycyclic peptide is coupled with a conjugate (DOTA or FITC) and a linker, so that a monovalent or divalent molecular probe can be constructed; the molecular probe has high specificity, high stability and good biocompatibility, can be used for accurate imaging and quantitative evaluation of HER2 positive cells / tumors and diagnosis and targeted therapy of HER2 signal path related diseases through radionuclide labeling or fluorescence labeling, and provides a novel tool and a transformation basis for early diagnosis and accurate treatment of HER2 positive solid tumors.

The present invention addresses the problem of providing a peptide cyclization technology that makes it possible to obtain a molecule that can be used as a cyclic peptide. The problem is solved by this chain molecule that comprises, in order of arrangement, a PNA chain (a) comprising a base sequence (a), a peptide chain capable of forming a cyclic peptide, and a PNA chain (b) comprising a base sequence (b).